Navigation Links
Avexegen Therapeutics Announces Exclusive License Agreement with Children’s Hospital Los Angeles
Date:3/20/2017

Avexegen Therapeutics Inc., an innovative biotechnology company developing novel therapies for gastrointestinal (GI) disorders, today announced that it has entered into an exclusive global license agreement with Children’s Hospital Los Angeles (CHLA) for Neuregulin-4 (NRG-4) for therapies in inflammatory bowel disease including Necrotizing Enterocolitis (rare orphan disease) as well as Crohn’s Disease and Ulcerative Colitis.

“With this licensing deal, Avexegen will continue to advance on its strategy to develop therapies for high unmet need GI disorders,” said Artin Asadourian, CEO of Avexegen Therapeutics.

Mark Frey, PhD, a principal investigator at The Saban Research Institute of CHLA, has demonstrated NRG-4 therapeutic proof of concept in preclinical models of NEC and inflammatory bowel disease. NRG-4’s efficacy is mediated by dual mechanisms that promote mucosal healing: the direct protection of the intestinal barrier and the suppression of inflammatory cytokines via its novel immunomodulatory action.

Currently, there are no FDA approved drugs for the treatment or prevention of Necrotizing Enterocolitis (NEC), which is a life-threatening disease that afflicts very low birth weight premature infants. NRG-4 has the potential to be the first such therapy for NEC.

About Avexegen Therapeutics, Inc.
Avexegen, founded in December 2014, is an emerging privately held biotech company based in San Diego, CA focused on developing novel treatments for a broad spectrum of inflammatory GI disorders. For more information please visit http://www.avexegen.com

Read the full story at http://www.prweb.com/releases/2017/03/prweb14155590.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related biology technology :

1. Protagonist Therapeutics to Present at the Oppenheimer & Co. Healthcare Conference
2. eFFECTOR Therapeutics Lead Product Candidate, eFT508, Receives Orphan Designation from FDA for Treatment of Diffuse Large B-Cell Lymphoma
3. Audentes Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update
4. Orexigen Therapeutics to Provide Business Update and Discuss Fourth Quarter and Year End 2016 Financial Results on March 28, 2017
5. UNIAPAC Foundation Think Tank in Paris selects Renova Therapeutics CEO and Co-founder as keynote speaker for annual meeting
6. Envisia Therapeutics To Present At American Glaucoma Society 2017 Annual Meeting
7. Stealth BioTherapeutics Initiates Observational Study of Patients With Mitochondrial Myopathy
8. Sangamo Therapeutics Announces Presentation At The Cowen And Company 37th Annual Health Care Conference
9. Nektar Therapeutics Reports Fourth Quarter and Year-End 2016 Financial Results
10. Sangamo Therapeutics Reports Fourth Quarter And Full Year 2016 Financial Results
11. Capricor Therapeutics to Present at Two Investor Conferences in March
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... firm Parks Associates announced today that Tom Kerber , ... Meeting , October 11 in Scottsdale, Arizona . Kerber ... smart safety and security products impact the competitive landscape. ... Parks Associates: Smart Home Devices: Main Purchase Driver ... "The residential security market has experienced continued growth, and the introduction ...
(Date:10/9/2017)... 2017  BioTech Holdings announced today identification and ... ProCell stem cell therapy prevents limb loss in ... demonstrated that treatment with ProCell resulted in more ... compared to standard bone marrow stem cell administration.  ... reduction of therapeutic effect.  ...
(Date:10/9/2017)... ... October 09, 2017 , ... ... the medical journal, Epilepsia, Brain Sentinel’s SPEAC® System which uses the surface ... detecting generalized tonic-clonic seizures (GTCS) using surface electromyography (sEMG). The prospective multicenter ...
(Date:10/6/2017)... (PRWEB) , ... October 06, 2017 , ... ... entrepreneurship within the healthcare and technology sector at their fourth annual Conference where ... featuring 30 inspiring speakers and the ELEVATE pitch competition showcasing early stage digital ...
Breaking Biology Technology:
(Date:3/30/2017)... -- Trends, opportunities and forecast in this market to ... AFIS, iris recognition, facial recognition, hand geometry, vein recognition, ... industry (government and law enforcement, commercial and retail, health ... and by region ( North America , ... , and the Rest of the World) ...
(Date:3/28/2017)... India , March 28, 2017 ... IP, Biometrics), Hardware (Camera, Monitors, Servers, Storage Devices), Software ... Vertical, and Region - Global Forecast to 2022", published ... Billion in 2016 and is projected to reach USD ... between 2017 and 2022. The base year considered for ...
(Date:3/24/2017)... 2017 The Controller General of Immigration from Maldives ... Algeen have received the prestigious international IAIR Award for the most ... Reading ... Maldives ... Abdulla Algeen (small picture on the right) have received the IAIR award ...
Breaking Biology News(10 mins):